A powerful case study showed a patient with well-controlled LEMS, who initially deferred immunotherapy, was later treated with durvalumab plus chemotherapy upon recurrence. She achieved a complete radiographic response and continued durvalumab maintenance for 10 months without worsening her LEMS, supporting the cautious use of immunotherapy in this population.

Instead of automatically ruling out immunotherapy for cancer patients with co-existing autoimmune diseases like rheumatoid arthritis, oncologists collaborate with experienced rheumatologists. This specialist team can assess the patient's specific condition, manage risks, and confidently advise whether it is safe to proceed with anti-PD-1 therapy, enabling more patients to access effective treatments.

An ongoing study is assessing routine LEMS antibody screening for all SCLC patients. However, a positive result in an asymptomatic patient could wrongly deter oncologists from using highly effective therapies like immunotherapy or T-cell engagers due to unsubstantiated fears of triggering a neurologic flare, for which there is currently no evidence.

While treating the underlying small cell lung cancer is primary and can improve LEMS, it often fails to fully resolve debilitating muscle weakness. Supportive care medications, such as the FDA-approved amifampradine, are crucial to manage neurologic symptoms, maintain quality of life, and prevent permanent disability.

Not all paraneoplastic syndromes are equal in severity. Endocrine syndromes like SIADH are generally manageable and reversible with anti-cancer therapy. In contrast, neurologic syndromes like LEMS are more debilitating and persistent, causing significant disability and posing a greater challenge when considering aggressive treatments like immunotherapy.

T-cell engagers (TCEs) are likely to be safer in autoimmune conditions than in cancer. Autoimmune patients have a relatively normal B-cell count, unlike the massive proliferation in hematologic cancers. This lower target cell burden naturally limits the scale of T-cell activation and inflammatory toxicity.

Experts express concern that the paraneoplastic syndrome LEMS is frequently missed in SCLC patients. Its primary symptom, proximal muscle weakness, is often attributed to the cancer itself or treatment side effects, leading clinicians to overlook the specific diagnostic test for this distinct and potentially treatable condition.

Contrary to fears based on T-cell engagers in hematologic cancers, CRS with the DLL3 bispecific tarlatamab in SCLC is typically mild and easily managed. An expert describes it as "scary until you're treating patients and then you find that it's pretty anticlimactic," reassuring community oncologists about the therapy's safety profile.

Oncologists should be highly suspicious of LEMS when a patient's functional decline is disproportionate to their cancer's response to treatment. If imaging shows tumors are shrinking but the patient is getting weaker, this mismatch is a critical signal that a distinct paraneoplastic process is at play and warrants immediate investigation.